

MARINUS PHARMACEUTICALS INC  
Form 8-K  
April 21, 2016

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report

(Date of earliest event reported)

**April 19, 2016**

**MARINUS PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-36576**  
(Commission File Number)

**20-0198082**  
(I.R.S. Employer  
Identification No.)

**170 N Radnor Chester Rd, Suite 250**  
**Radnor, PA 19087**  
(Address of principal executive offices)

**19087**  
(Zip Code)

Registrant's telephone number, including area code: **(484) 801-4670**

Edgar Filing: MARINUS PHARMACEUTICALS INC - Form 8-K

**Three Radnor Corporate Center**

**100 Matsonford Road, Suite 304**

**Radnor, PA 19087**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  
  - o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  
  - o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  
  - o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

**Item 5.07. Submission of Matters to a Vote of Security Holders.**

On April 19, 2016, Marinus Pharmaceuticals, Inc. (the Company) held its 2016 Annual Meeting of Shareholders. At the meeting, the shareholders voted on: (1) the election of two Class II directors and (2) the ratification of the appointment of KPMG LLP as the Company's independent registered public accounting firm for the year ending December 31, 2016. The voting results on these proposals were as follows:

**Proposal 1: Election of Two Class II Directors**

Director	Votes For	Withheld	Broker Non-votes
Anand Mehra, M.D.	13,818,790	49,200	2,499,859
Nicole Vitullo	10,820,573	3,047,417	2,499,859

**Proposal 2: Ratification of the appointment of KPMG LLP as the Company's independent registered public accountant firm for the year ending December 31, 2016**

Votes For	Votes Against	Abstentions
16,253,995	89,518	24,336

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MARINUS PHARMACEUTICALS, INC.

By: /s/ Edward Smith  
Edward Smith,  
Vice President, Chief Financial Officer,  
Secretary and Treasurer

Date: April 21, 2016